Sachs Associates’ Post

Explore how Life Science Group Ltd (LSG) is revolutionising lateral flow device technology with groundbreaking advancements in lung cancer detection using urine as a test medium. From antibody design to finished device delivery, LSG is leading the way in efficiency and accuracy. Read more about this game-changing innovation at https://lnkd.in/e37TzfNs  #LifeScienceGroup #Innovation #DiagnosticTechnology

Our latest poster from AACR24 introduces SynAI, a state-of-the-art AI-driven solution poised to redefine the approach to predicting drug synergism in cancer cell lines. By harnessing the power of compound SMILE sequences, SynAI offers a swift, efficient, and cost-effective method for identifying promising therapeutic combinations. Download this poster to discover: ✅SynAI's unmatched flexibility and efficiency in drug synergy prediction. ✅The AI core's sophisticated methodology, trained on comprehensive cancer cell line datasets. ✅SynAI's evolutionary potential to refine cancer treatment discovery with ongoing data integration. ➡️ https://hubs.la/Q02JdyRQ0 #AI #DrugSynergy

Our latest poster from AACR24 introduces SynAI, a state-of-the-art AI-driven solution poised to redefine the approach to predicting drug synergism in cancer cell lines. By harnessing the power of compound SMILE sequences, SynAI offers a swift, efficient, and cost-effective method for identifying promising therapeutic combinations. Download this poster to discover: ✅SynAI's unmatched flexibility and efficiency in drug synergy prediction. ✅The AI core's sophisticated methodology, trained on comprehensive cancer cell line datasets. ✅SynAI's evolutionary potential to refine cancer treatment discovery with ongoing data integration. ➡️ https://bit.ly/44dDXM3 #AI #DrugSynergy

Are biomarkers the key to diagnosing and treating cancer effectively? 🔑 They help identify patients who will benefit most from targeted therapies, making clinical trials faster and more efficient. However, reliable biomarkers are still lacking for many cancers. 🔎 At Parexel, our team of experts is leveraging diverse data streams and exciting advances in #AI and #machinelearning to fast-track cancer research and improve patient outcomes. We asked Angela Qu to describe how recent advances in multi-omics and computational analytics accelerate the discovery and validation of biomarkers in precision oncology. Read her responses at the link below! #Biomarkers #Oncology #PrecisionOncology #NovelInsights

Are biomarkers the key to diagnosing and treating cancer effectively? 🔑 They help identify patients who will benefit most from targeted therapies, making clinical trials faster and more efficient. However, reliable biomarkers are still lacking for many cancers. 🔎 At Parexel, our team of experts is leveraging diverse data streams and exciting advances in #AI and #machinelearning to fast-track cancer research and improve patient outcomes. We asked Angela Qu to describe how recent advances in multi-omics and computational analytics accelerate the discovery and validation of biomarkers in precision oncology. Read her responses at the link below! #Biomarkers #Oncology #PrecisionOncology #NovelInsights

Are biomarkers the key to diagnosing and treating cancer effectively? 🔑 They help identify patients who will benefit most from targeted therapies, making clinical trials faster and more efficient. However, reliable biomarkers are still lacking for many cancers. 🔎 At Parexel, our team of experts is leveraging diverse data streams and exciting advances in #AI and #machinelearning to fast-track cancer research and improve patient outcomes. We asked Angela Qu to describe how recent advances in multi-omics and computational analytics accelerate the discovery and validation of biomarkers in precision oncology. Read her responses at the link below! #Biomarkers #Oncology #PrecisionOncology #NovelInsights

Are biomarkers the key to diagnosing and treating cancer effectively? 🔑 They help identify patients who will benefit most from targeted therapies, making clinical trials faster and more efficient. However, reliable biomarkers are still lacking for many cancers. 🔎 At Parexel, our team of experts is leveraging diverse data streams and exciting advances in #AI and #machinelearning to fast-track cancer research and improve patient outcomes. We asked Angela Qu to describe how recent advances in multi-omics and computational analytics accelerate the discovery and validation of biomarkers in precision oncology. Read her responses at the link below! #Biomarkers #Oncology #PrecisionOncology #NovelInsights

Are biomarkers the key to diagnosing and treating cancer effectively? 🔑 They help identify patients who will benefit most from targeted therapies, making clinical trials faster and more efficient. However, reliable biomarkers are still lacking for many cancers. 🔎 At Parexel, our team of experts is leveraging diverse data streams and exciting advances in #AI and #machinelearning to fast-track cancer research and improve patient outcomes. We asked Angela Qu to describe how recent advances in multi-omics and computational analytics accelerate the discovery and validation of biomarkers in precision oncology. Read her responses at the link below! #Biomarkers #Oncology #PrecisionOncology #NovelInsights

Are biomarkers the key to diagnosing and treating cancer effectively? 🔑 They help identify patients who will benefit most from targeted therapies, making clinical trials faster and more efficient. However, reliable biomarkers are still lacking for many cancers. 🔎 At Parexel, our team of experts is leveraging diverse data streams and exciting advances in #AI and #machinelearning to fast-track cancer research and improve patient outcomes. We asked Angela Qu to describe how recent advances in multi-omics and computational analytics accelerate the discovery and validation of biomarkers in precision oncology. Read her responses at the link below! #Biomarkers #Oncology #PrecisionOncology #NovelInsights

Natera’s latest results from the CIRCULATE-Japan GALAXY study, showcasing the prognostic and predictive value of Signatera and actionable biomarkers in colorectal cancer The function of therapy directed by biomarkers in operable colorectal cancer remains under exploration. Circulating tumor DNA has surfaced as a less invasive indicator for identifying residual molecular disease and forecasting relapse. The integration of tumor-informed ctDNA analysis, which merges tumor sequencing with MRD detection into a streamlined process, appears promising for its potential to be seamlessly adopted in clinical settings. Experience the Best of Expert Insights and Comprehensive Analysis with DelveInsight Business Research LLP's American Society of Clinical Oncology (ASCO) 2024 Exclusive Coverage @ https://lnkd.in/gqU_hSci #asco24 #ascoconference #asco #CIRCULATEJapanGALAXYStudy #NateraSignatera #ColorectalCancerBiomarkers #PrognosticValue #PredictiveBiomarkers #CirculatingTumorDNA #ctDNATesting #MolecularResidualDisease #MRDDetection #BiomarkerGuidedTherapy #CRCCancerResearch #PersonalizedMedicine #OncologyInnovation #CancerBiomarkers #ActionableBiomarkers #CancerRecurrencePrediction #TumorSequencing #ClinicalOncology #CancerTreatmentAdvances #GenomicMedicine #PrecisionOncology